Robert W Baird

GREENWICH, Conn., Oct. 15 /PRNewswire/ -- North Castle Partners today announced that it has reached a definitive agreement to sell Enzymatic Therapy, Inc., a leader in the natural medicine and nutritional supplements category, to Nature's Way, a leader in herbal and nutritional science and a subsidiary of the Schwabe Pharmaceutical group. For North Castle Partners, a leading private equity firm focused exclusively on consumer businesses that benefit from "Healthy Living and Aging" trends, the transaction represents the fourth sale of a portfolio company to a strategic acquirer during the past two years. Terms of the transaction, which is subject to government approval, were not disclosed. Chip Baird, Managing Director of North Castle Partners, said, "We are proud of our successful partnership with the Enzymatic management team. As a focused fund, North Castle identifies high-growth, niche segments within larger industries, and partners with extraordinary management teams to build great ...

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)-- Life Science Intelligence (LSI) announced this month that another new group of 37 mostly privately-held medtech companies has recently been added to the EMT (Emerging Medical Technologies)(R) Database: www.emergingmedicaltechnologies.com. According to LSI, this latest round of companies is collectively seeking over $210M ($31M Series A, $124.5M Series B, $35M Series D, $20M Undisclosed). Many of the companies are also actively pursuing strategic partnerships and licensing deals with large medtech companies. LSI's EMT ...

Not So Fast!
Here’s a link to listen to an Audio Version of the report:


With stocks having blasted higher by more than 11% during Monday’s spectacular rebound and Japan’s Nikkei up more than +14% overnight, it wasn’t exactly surprising to see stock futures bounding higher in pre-market trading yesterday. And sure enough, traders didn’t disappoint as the Dow stepped lively to the tune of a 407 point gain in the first 5 minutes of the session.

But right at that moment, somebody must have grabbed a calculator and figured out that the Dow had blasted up 1,912 points or a whopping 24.2% since – wait for it – about lunchtime on Friday, because the rally stopped abruptly right then and there.

To be clear, there wasn’t any news to cause the celebration to suddenly and without warning, stop in its tracks. No, the simple fact of the matter ...

BOSTON, Oct. 15 /PRNewswire-FirstCall/ -- Perceptive Informatics, one of the industry's leading eClinical technology providers and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), announced today that it has enhanced its TrialWorks(R) solution, a specialized Clinical Trial Management System (CTMS) designed specifically for small and mid-size companies. The enhanced 2.1 version of the TrialWorks solution has updated functionality for reporting, data transfer, and analyzing study information. The system is also aligned with new requirements for uploading information to the ClinicalTrials.gov website, a registry of federally and privately supported clinical trials conducted in the United States and around the world. "To meet the unique needs of small and mid-size biopharmaceutical companies conducting more complex, global clinical programs, the new features of the TrialWorks system provide a greater degree of flexibility and configurability for these demanding studies," said Steve Kent, President of Perceptive Informatics. "Since CTMS tracks, manages, and reports on every aspect of a clinical study, we believe ...

Robert W. Baird upgrades Fifth ...